BillionToOne, Inc. Class A Common Stock(BLLN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 6 days
PROFIT SINCE LAST BUY
-7.71% ▼
LAST CLOSE
$105.15
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BLLN

11/13/2026: BLLN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

BillionToOne is a commercial-stage molecular diagnostics company that develops high-resolution prenatal screening and oncology liquid biopsy tests using its proprietary QCT platform. The company's main strengths include rapid revenue growth, solid gross margins, and strong adoption of its flagship UNITY prenatal screening suite. Its primary investment story centers on scaling its oncology portfolio and expanding health system integrations to capture broader market share. Key risks involve intense competition from larger diagnostics peers, potential reimbursement headwinds, and execution challenges in scaling new assays. The stock suits growth-oriented investors willing to navigate short-term volatility while monitoring quarterly test volume expansion and new product adoption milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitRapid top-line expansion and large addressable markets align well with growth mandates.
Momentum investorStrong fit while signal remains positiveHigh trading volume and strong analyst sentiment create favorable conditions during uptrends.
Value investorWeak fitTrading at high growth-adjusted multiples leaves little margin of safety for traditional value parameters.
Dividend investorWeak fitThe company retains all earnings to fund research and expansion, paying no dividends.
Low-risk investorWeak fitClinical development uncertainties and growth stock volatility expose risk-averse holders to drawdowns.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighGrowth-stage diagnostics stocks experience sharp price swings based on market sentiment and earnings reports.
Valuation riskMedium / highPriced for perfection, any growth deceleration or earnings miss can trigger multiple compression.
Competition risk (Natera and Guardant Health)HighIntense competition from well-capitalized laboratory peers can pressure pricing and market share gains.
Business qualityStrongProprietary QCT technology delivers high gross margins and differentiated product utility.
Dividend incomeLow / noneNo dividend is distributed, making total return entirely dependent on stock price appreciation.
Execution riskMedium / highSuccessful scaling of oncology sales and EHR integration channels is critical to meeting long-term targets.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.02B USD
Price to earnings Ratio 114.29
1Y Target Price 128.29
Price to earnings Ratio 114.29
1Y Target Price 128.29
Volume (30-day avg) 596.7K shares
Beta -
52 Weeks Range 61.96 - 150.44
Updated Date 11/15/2026
52 Weeks Range 61.96 - 150.44
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.92

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -17%
Avg. Invested days 27
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BLLN receives a 4-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
BLLN has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+117.9%) and solid cash generation (FCF margin 5.2%) are partially offset by soft profitability (net margin 2.4%).

Financial Health Rating

★★★★★
BLLN's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 81.0%). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is BLLN's strongest growth driver at +133.6% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+100.0%, strong) and earnings growth (+117.9%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 48.2% and approximately 67.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 28.63% supports management-shareholder alignment.

Top 5 Institutional Investors

Adams Street Partners LLC 3.74%
Baillie Gifford & Co Limited. 2.36%
T. Rowe Price Associates, Inc. 2.21%
Vanguard Portfolio Management, LLC 1.84%
Amvescap Plc. 1.82%

Unit Economics (Per $1K Revenue)

★★★★★
BLLN generates approximately $683 of gross profit, $53 of operating income, and $52 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and solid cash conversion support a 3-star rating, while capital efficiency is solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 3.93%

Quantitative Style Profile

★★★★★
BLLN has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Quality TiltLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Prenatal Screening TestingCommercialization of the UNITY portfolio assessing fetal chromosomal and genetic risks from maternal blood draws.This is the core revenue engine, providing stable, high-margin cash flows from routine obstetrical testing.
Oncology Liquid BiopsySales of Northstar Select and Northstar Response panels for cancer therapy selection and disease monitoring.This segment acts as the primary secondary growth catalyst targeting precision oncology markets.

Earnings Date

Report Date 2026-11-04
When After Market
Estimate 0.16
Actual 0.32

Profitability

Profit Margin 10.52%
Operating Margin (TTM) 10.23%

Management Effectiveness

Return on Assets (TTM) 5.14%
Return on Equity (TTM) 13.23%

Valuation

Trailing PE 114.29
Forward PE 64.1
Enterprise Value 4.60B
Price to Sales(TTM) 11.5
Enterprise Value 4.60B
Price to Sales(TTM) 11.5
Enterprise Value to Revenue 10.54
Enterprise Value to EBITDA 73.43
Shares Outstanding 43.27M
Shares Floating 29.34M
Shares Outstanding 43.27M
Shares Floating 29.34M
Percent Insiders 28.63
Percent Institutions 48.21

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.